Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Lymphoma
Interventions
DRUG

Carmustine

300 mg/m\^2 IV for 1 Day

DRUG

Etoposide

Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

DRUG

Cytarabine

Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

DRUG

Melphalan

140 mg/m\^2 IV x 1 Day

DRUG

Rituximab

Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00472056 - Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | Biotech Hunter | Biotech Hunter